Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alitair Licenses Erdosteine from Edmond Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alitair Licenses Erdosteine from Edmond Pharma

Will seek orphan drug designation for bronchiectasis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alitair Pharmaceuticals has entered a definitive agreement to license Erdosteine, a mucolytic compound with antibacterial, anti-inflammatory, and antioxidant properties, from Edmond Pharma for development as an orphan drug in the U.S. and Canada. Financial terms were not disclosed.
 
Alitair president and chief executive officer William Howard said, “We are delighted to have licensed Erdosteine from Edmond Pharma. Erdosteine is currently approved in 30 countries for the treatment of chronic bronchitis and chronic obstructive pulmonary disorder, or COPD, and it is approved in four countries to treat bronchiectasis. We will seek an orphan drug designation for Erdosteine to treat bronchiectasis in the United States, which affects approximately 130,000 people.” 
 
Roberto Teruzzi, chief executive officer of Edmond Pharma S.r.l. holding company, added, “We at Edmond Pharma are very excited to have licensed Erdosteine to Alitair. Erdosteine was discovered years ago in our R&D labs in Italy and is now successfully distributed in several markets. Erdosteine is a very safe and effective drug with a unique pharmacological profile. We are very confident that, thanks to the cooperation with our partner Alitair, Erdosteine will play an important role in treating bronchiectasis patients in the U.S.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics